- Q1 2024 Cardiff Oncology Inc Earnings Call TranscriptMay 02, 2024$4.48 (+5.91%)Earnings
- Q4 2023 Cardiff Oncology Inc Earnings Call TranscriptFeb 29, 2024$1.77 (-3.02%)Earnings
- Q3 2023 Cardiff Oncology Inc Earnings Call TranscriptNov 02, 2023$1.14 (+8.57%)Earnings
- Cardiff Oncology Inc Clinical Update Call TranscriptSep 26, 2023
- Cardiff Oncology Inc Clinical and Corporate Update Call TranscriptAug 07, 2023
- Cardiff Oncology Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Cardiff Oncology Inc at Cowen Health Care Conference- GI/GU Oncology Panel TranscriptMar 07, 2023
- Cardiff Oncology Inc at JMP Securities Hematology Oncology Summit (Virtual) TranscriptDec 07, 2022
- Cardiff Oncology Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Cardiff Oncology Inc to Provide a Clinical and Corporate Update Call TranscriptSep 12, 2022
- Cardiff Oncology Inc to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer at ASCO-GI TranscriptJan 18, 2022
- Cardiff Oncology Inc to Discuss New Data from Lead Clinical Program in KRAS-mutated mCRC Webinar TranscriptSep 08, 2021
- Cardiff Oncology Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Cardiff Oncology Inc KOL Webinar TranscriptApr 12, 2021
- Cardiff Oncology Inc Discusses KRAS Mutations in Cancer TranscriptOct 14, 2020
- Cardiff Oncology, Inc. - Special Call TranscriptSep 23, 2020
- Cardiff Oncology Inc Onvansertib Clinical Trials TranscriptMay 18, 2020
- Trovagene Inc at Needham Healthcare Conference TranscriptApr 15, 2020
- Trovagene Inc Business Update Conference Call TranscriptJun 07, 2019
Cardiff Oncology Inc to Discuss New Data from Lead Clinical Program in KRAS-mutated mCRC Webinar Transcript
Good afternoon, and welcome to the Cardiff Oncology Data Presentation Webinar. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Cardiff Oncology website following the conclusion of the event.
Before we go further, I'd like to remind all listening that certain statements in this presentation are forward-looking within the meaning of the Private Litigation Reform Act of 1995 as disclosed in this slide. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements, and investors should read the risk factors set forth in Cardiff Oncology's Form 8-K for the year-end December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission.
While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)